Description
HCG (Human Chorionic Gonadotropin) is a glycoprotein hormone naturally produced by the syncytiotrophoblast of the placenta during pregnancy. Structurally, HCG consists of an alpha and a beta subunit, the alpha subunit being identical to that of LH, FSH and TSH. The beta subunit gives HCG its specific biological activity.
In research literature, HCG is an established compound for studies on the hypothalamic-pituitary-gonadal axis (HPG axis). The central mechanism: HCG binds to the LH receptor in Leydig cells of the testes (or theca cells of the ovaries) and stimulates steroidogenesis there. In male models, this leads to increased testosterone synthesis; in female models, to stimulation of estrogen production.
In the research context of the HPG axis, HCG is particularly interesting because it mimics the natural LH signal but has a substantially longer half-life (approximately 24-36 hours versus a few hours for LH). This pharmacokinetic profile makes the compound a clinical research tool for studies that aim to model LH signaling over longer time spans.
A particularity: HCG is offered in two variants, a 5000iu unit (standard) and a 10000iu unit (for more extensive research setups). The choice of unit depends on the study design.
HCG is available in 5000iu and 10000iu vials, each as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
HCG is considered well characterized per study reports, but as a gonadotropin it intervenes directly in the hormone axis, which sets its risk profile apart from that of pure tissue peptides.
Observed in research and user reports:
- Estrogenic effects: stimulation of steroidogenesis can increase testosterone production, part of which aromatizes to estradiol. The literature documents estrogen-mediated effects such as water retention or breast tissue irritation as a result.
- Hormone axis intervention: continuous LH receptor stimulation can shift the endogenous regulation of the HPG axis in preclinical models. The long half-life pharmacokinetics amplify this effect.
- Injection site: mild redness, pressure or transient irritation at the injection site is among the most common observations.
- No long-term data: robust human studies on longer-term non-clinical use do not exist. The profile rests on clinical short-term data and animal models.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling - PLoS One 2012: Cell study on the shared LH/hCG receptor: hCG was about five times more potent than LH in stimulating cAMP production, whereas LH activated ERK and AKT signaling more strongly.
- Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression - Journal of Clinical Endocrinology & Metabolism 2005: Randomized study in 29 healthy men: intratesticular testosterone fell by 94% under testosterone enanthate, while added low-dose hCG kept it within the normal range in a dose-dependent manner.
- Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy - Journal of Urology 2013: Retrospective review of 26 men on testosterone replacement with concomitant low-dose hCG: semen parameters remained stable for more than a year and no man became azoospermic.
- Biological functions of hCG and hCG-related molecules - Reproductive Biology and Endocrinology 2010: Review of the four hCG variants (regular, hyperglycosylated and pituitary hCG plus the free beta subunit) and their separate biological functions.
